Skip to content
Contact Us
Technology
Clinical Program
Discovery Platform
Pipeline
About Us
News
Technology
Clinical Program
Discovery Platform
Pipeline
About Us
News
Award-Winning Innovation: MBrace was shortlisted Best New Drug Developer and awarded Most Promising Clinical Candidate for MBRC-101 at the 11th Annual World ADC Awards
Technology
Clinical Program
Discovery Platform
Pipeline
About Us
News
Contact Us
Technology
Clinical Program
Discovery Platform
Pipeline
About Us
News
Contact Us
Back
Press Releases
TPS3161: A Multi-center, Open-Label Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors
June 1, 2024
More news
Read the
Press Releases
→
MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting
More news
Read the
Press Releases
→
MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting
For more information about MBrace’s products or programs please contact us at:
info@mbracetrx.com
